E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis.
E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis.
复制标题
E-钙粘蛋白表达作为卵巢癌患者的预后因素：一项荟萃分析。
DOI：
10.18632/oncotarget.18898
复制
发表时间：
2017-10-06
期刊：
影响因子：
--
通讯作者：
Xu P
中科院分区：
文献类型：
--
作者：
Dai C;Cao J;Zeng Y;Xu S;Jia X;Xu P
上皮钙粘蛋白（E-cadherin）下调在卵巢癌中的预后作用已被评估多年，但结果仍不确定。我们研究的目的是评估这个问题。通过检索PubMed、EMBASE和科克伦数据库确定合格的研究。共纳入17项研究的1562例患者，以评估E-cadherin表达与卵巢癌患者总生存期/无进展生存期和临床病理特征之间的关系。计算风险比（HR）或比值比（OR）及其95%置信区间（95%CI）以估计效果。采用纽卡斯尔渥太华质量评估量表对17项研究的质量进行评价。我们还进行了亚组分析、发表偏倚和敏感性分析。结果显示，E-cadherin表达阴性者生存率低（HR = 1.90，95% CI = 1.50-2.40）。然而，E-cadherin阴性与不良无进展生存期无关（HR = 1.19，95%CI = 0.86-1.64）。E-cadherin的阴性表达与FIGO分期密切相关（OR = 0.42，95%CI = 0.31-0.57），肿瘤分级（OR = 0.48，95% CI = 0.34-0.67）、转移（OR = 0.13，95% CI = 0.07-0.26）、复发（OR = 0.48，95% CI = 0.29-0.79）。Meta分析显示E-cadherin表达阴性可能是卵巢癌患者预后不良的预测因素。
The prognostic role of epithelial cadherin (E-cadherin) downregulation in ovarian cancer has been assessed for years while the results remain inconclusive. The aim of our study was to assess this issue. Eligible studies were identified through searches of PubMed, EMBASE and Cochrane Database. In total, 1562 patients from 17 studies were included to assess the association between E-cadherin expression and overall survival/progression-free survival and clinicopathological characteristics of ovarian cancer patients. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence interval (95% CI) were calculated to estimate the effect. The quality of 17 studies was evaluated using the Newcastle Ottawa Quality Assessment Scale. We also performed subgroup analysis, publication bias and sensitivity analysis in this meta-analysis. The results showed that negative E-cadherin expression significantly predicted poor overall survival of ovarian cancer patients (HR = 1.90, 95% CI = 1.50–2.40). However, negative E-cadherin was not associated with poor progression-free survival (HR = 1.19, 95% CI = 0.86–1.64). Moreover, Negative E-cadherin expression was distinctly associated with FIGO stage (OR = 0.42, 95% CI = 0.31–0.57), tumor grade (OR = 0.48, 95% CI = 0.34–0.67), metastasis (OR = 0.13, 95% CI = 0.07–0.26) and recurrence (OR = 0.48, 95% CI = 0.29–0.79). This meta-analysis revealed that negative E-cadherin expression might be a predicative factor of poor prognosis in ovarian cancer patients.